Park Ha Biological Technology stock rises on upcoming ticker symbol change
Investing.com -- Thermo Fisher Scientific Inc. (NYSE:TMO) reported third-quarter results that exceeded analyst expectations, with adjusted earnings per share and revenue both surpassing consensus estimates. Shares of the scientific equipment maker rose 1.4% following the announcement.
The company posted adjusted EPS of $5.79 for the quarter ended September 27, 2025, beating the analyst estimate of $5.50 by $0.29. Revenue grew 5% to $11.12 billion, above the consensus estimate of $10.91 billion and representing a 3% organic growth rate compared to the same period last year.
"Our team did an outstanding job and delivered excellent operational performance in the quarter, reflecting the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
The company’s adjusted operating margin improved to 23.3% from 22.3% in the third quarter of 2024, while GAAP EPS remained relatively flat at $4.27 compared to $4.25 in the year-ago period.
During the quarter, Thermo Fisher launched several new products, including the FDA-approved Oncomine Dx Express Test for non-small cell lung cancer and the Olink Target 48 Neurodegeneration panel for research into diseases such as Alzheimer’s and Parkinson’s.
The company also strengthened its strategic position by completing acquisitions of a Filtration and Separation business from Solventum and Sanofi’s Ridgefield, New Jersey, sterile fill-finish site. Additionally, Thermo Fisher repurchased $1.0 billion of stock during the quarter and established a strategic collaboration with OpenAI to increase the use of artificial intelligence across its operations.